BioCentury | Apr 10, 2019
Distillery Therapeutics

Imidazopyrimidine-based inhibitor of Leishmania proteasome identified to treat visceral leishmaniasis

...Inc., Profounda Inc., Roche and Zydus Cadila Group market Impavido, an alkylphosphocholine analog that inhibits cholinephosphate cytidyltransferase...
BioCentury | Aug 24, 2017
Translation in Brief

The skinny on leishmaniasis

...Astellas Pharma Inc. (Tokyo:4503) and Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506); and Impavido miltefosine, a cholinephosphate cytidyltransferase...
BioCentury | Jul 3, 2017
Preclinical News

Paper names scaffold protein as target for infection

...treat leishmaniasis. The drug is an alkylphosphocholine analog that inhibits cholinephosphate cytidyltransferase . Chris Lieu Impavido Miltefosine Knight Therapeutics Inc. Profunda Inc. Cholinephosphate cytidyltransferase...
BioCentury | Dec 10, 2015
Distillery Therapeutics

Therapeutics: An undetermined target

...Therapeutics Inc. , Roche and Zydus Cadila Group market Impavido, an alkylphosphocholine analog that inhibits cholinephosphate cytidyltransferase...
BioCentury | Aug 18, 2014
Company News

Knight Therapeutics infectious news

...fellow specialty pharma Endo International plc (NASDAQ:ENDP; TSX:ENL, Dublin, Ireland). The alkylphosphocholine analog that inhibits cholinephosphate cytidyltransferase...
BioCentury | Apr 21, 2014
Company News

Knight Therapeutics, Medicure cardiovascular news

...Impavido to treat cutaneous, mucosal and visceral leishmaniasis last month. The alkylphosphocholine analog that inhibits cholinephosphate cytidyltransferase...
BioCentury | Mar 24, 2014
Clinical News

Impavido miltefosine regulatory update

...plc (NASDAQ:ENDP; TSX:ENL, Dublin, Ireland) (see BioCentury, March 10). Impavido, an alkylphosphocholine analog that inhibits cholinephosphate cytidyltransferase...
BioCentury | May 30, 2000
Clinical News

Apra: Phase II

...Therapeutics Inc. (CTIC), Seattle, Wash. Product: Apra (CT-2584) Business: Cancer Therapeutic category: Cytotoxic Target: CTP: cholinephosphate cytidyltransferase...
BioCentury | May 30, 2000
Clinical News

Apra: Phase II

...Therapeutics Inc. (CTIC), Seattle, Wash. Product: Apra (CT-2584) Business: Cancer Therapeutic category: Cytotoxic Target: CTP: cholinephosphate cytidyltransferase...
Items per page:
1 - 9 of 9